Bladder Cancer
Collecting electronic patient-reported outcomes via smartphone text messages in a bladder cancer RCT: A feasibility study.
- Details
Patient-reported outcome measures are increasingly used to assess symptoms, treatment tolerance, and quality of life (QoL) in oncology. Electronic patient-reported outcome measures (ePROM) offer advantages over paper questionnaires, but large-scale evidence using smartphone text messaging in clinical trials is limited.
Epidemiological Trends and Germline Variant Analysis of Young-Onset Bladder Cancer.
- Details
The incidence of bladder cancer (BCa) is rising worldwide. Recent reports suggest a disproportionate increase among younger individuals, raising questions about epidemiologic and genetic contributors to early-onset disease.
Genomic analysis of BCG unresponsive non-muscle-invasive bladder cancer identifies drivers of sensitivity to intravesical Gemcitabine/Docetaxel.
- Details
Intravesical gemcitabine/docetaxel (Gem/Doce) is an effective therapy for Bacillus Calmette- Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC), achieving 50% complete responses at 2 years.
Sarcopenia Weakens the Benefit of Bacillus Calmette-Guérin in Non-Muscle-Invasive Bladder Cancer: A Computed Tomography-Based Cohort Study.
- Details
Non-muscle-invasive bladder cancer (NMIBC) commonly recurs despite intravesical Bacillus Calmette-Guérin (BCG) therapy. Host factors that modify the effectiveness of BCG have not been completely defined.
A machine-learning approach to predict additional treatment after Bacillus Calmette-Guérin induction in non-muscle-invasive bladder cancer.
- Details
Non-muscle invasive bladder cancer (NMIBC) comprises ~ 75% of newly diagnosed bladder cancer, with high-risk NMIBC associated with high rates of recurrence and progression. Nearly 40% of patients experience a lack of efficacy with gold standard Bacillus Calmette-Guérin (BCG) therapy and current methods for predicting BCG response are limited.
An advanced in vitro bladder cancer model integrating bladder cancer spheroids into a healthy human urothelium for preclinical therapeutic testing.
- Details
Despite therapy advances, better solutions for refractory bladder cancer remain an unmet need. Human cell-based models may aid in better treatment translation. We introduce 3D-UHU-TU, a bladder cancer microtissue model which incorporates spheroids derived from low- and high-grade human bladder cancer cell lines (RT112 and T24 respectively) into a healthy human urothelium.
10-yr Outcomes of Senior Clinical Fellowship in Robot-assisted Radical Cystectomy (RARC) with focus on Intracorporeal Ileal Conduit Urinary Diversion: Aggregated Learning Curve Assessment and Achievement of the EAU-Robotic Urology Section (ERUS) RARC Curr
- Details
(1) To examine 10-yr outcomes of Robot-assisted Radical Cystectomy (RARC) with Intracorporeal Ileal Conduit (ICIC) performed by international clinical fellows within a 1-yr RCS-Eng Urothelial Senior Fellowship Programme.
Radiogenomic analysis of muscle-invasive bladder cancer using CT-based texture analysis.
- Details
Urothelial bladder cancer exhibits marked molecular and clinical heterogeneity. While genomic and transcriptomic profiling of muscle-invasive bladder cancer (MIBC) has revealed recurrent alterations with therapeutic and prognostic relevance, limited access to molecular testing constrains clinical use.
Evolution of treatment and oncological outcomes in patients undergoing radical cystectomy: a comparative analysis across two decades at a tertiary center.
- Details
Over the last two decades, significant advances in the perioperative management of muscle-invasive bladder cancer, such as enhanced recovery protocols, increased use of neoadjuvant chemotherapy, improved care pathways, and stronger multidisciplinary collaboration, have reshaped surgical outcomes.
Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing Schedules.
- Details
The potential impact of treatment sequencing in chemoimmunotherapy combinations remains underexplored. We evaluated 2 alternative dosing schedules of chemotherapy (cisplatin and gemcitabine [GC]) and an immune checkpoint inhibitor (CPI; atezolizumab [A]) for metastatic urothelial carcinoma (mUC).